GMED
Market read
The latest filing is mixed. 0 of 20 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 9 directly disclosed connections are confirming.
Invalidation: The isolated read changes if GMED's group or a disclosed connection begins moving with it.
Research brief
The latest filing is mixed. 0 of 20 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 9 directly disclosed connections are confirming.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“Other Income/(Expense), Net Six Months Ended June 30, Change (In thousands, except percentages) 2026 2025 $ % Other income/(expense), net $ 12,953 $ 8,167 $ 4,786 58.6 % Percentage of net sales 0.8 % 0.6 % Other income/(expense) increased by $4.8 million, or…”10-Q · Aug 6, 2026 ↗
“Research and Development Expenses Three Months Ended June 30, Change (In thousands, except percentages) 2026 2025 $ % Research and development $ 36,321 $ 39,954 $ (3,633) (9.1 %) Percentage of net sales 4.6 % 5.4 % The $3.6 million, or 9.1%, decrease in resea…”10-Q · Aug 6, 2026 ↗
“Restructuring Costs Six Months Ended June 30, Change (In thousands, except percentages) 2026 2025 $ % Restructuring costs $ 7,169 $ 13,547 $ (6,378) (47.1 %) Percentage of net sales 0.5 % 1.0 % The $6.4 million, or 47.1%, decrease in restructuring costs was p…”10-Q · Aug 6, 2026 ↗
“Cost of Sales Six Months Ended June 30, Change (In thousands, except percentages) 2026 2025 $ % Cost of sales (exclusive of amortization of intangibles) $ 475,505 $ 444,162 $ 31,343 7.1 % Percentage of net sales 30.7 % 33.1 % The $31.3 million, or 7.1%, incre…”10-Q · Aug 6, 2026 ↗
Valuation discipline
Price/sales 3.4× · EV/sales 3.3×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 14:05 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for GMED. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment
10-Q filed 2026-08-06 against the comparable filing from 2025-08-07.
Capital and cash conversion
Capital-spending intensity declined while free-cash-flow margin improved.
Capex, revenue, and operating cash flow are matched to the same reported duration. Reported accounting context, not a forecast or trading recommendation.
“Cost of Sales Six Months Ended June 30, Change (In thousands, except percentages) 2026 2025 $ % Cost of sales (exclusive of amortization of intangibles) $ 475,505 $ 444,162 $ 31,343 7.1 % Percentage of net sales 30.7 % 33.1 % The $31.3 million, or 7.1%, increase in cost of sales for the six months ended June 30, 2026 was primarily driven by the cost of sales from Nevro products of $8.9 million, an increase in freight cost of $7.9 million, an increase in product cost of $6.9 million driven primarily by higher volume, and an increase in depreciation of $3.3 million.”
“Other Income/(Expense), Net Six Months Ended June 30, Change (In thousands, except percentages) 2026 2025 $ % Other income/(expense), net $ 12,953 $ 8,167 $ 4,786 58.6 % Percentage of net sales 0.8 % 0.6 % Other income/(expense) increased by $4.8 million, or 58.6%, primarily driven by a net increase in interest income of $10.1 million, which was driven by a $7.3 million decrease in interest expense and a $2.9 million increase in interest income.”
“Amortization of Intangibles Six Months Ended June 30, Change (In thousands, except percentages) 2026 2025 $ % Amortization of intangibles $ 59,086 $ 58,991 $ 95 0.2 % Percentage of net sales 3.8 % 4.4 % Amortization of intangibles increased by $0.1 million, or 0.2%, primarily driven by the acquisition of intangibles in connection with the Nevro Merger, which contributed $3.4 million in expense in the current period as compared to $1.5 million in the same period of the prior year.”
Historical filing backfill generated after the original filing window. It is not part of Jodie's live track record.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“Pimenta improperly provided inventions to Alphatec Holdings, Inc., a competitor of NuVasive, without granting NuVasive the right of first negotiation under the Agreement.”
“Alphatec Holdings, Orthofix, Integra LifeSciences , ZimVie, Boston Scientific and other smaller public and private companies are also competitors of ours.”
Depended on by
“We believe that our primary competitors marketing implantable devices currently are Alphatec Holding Inc., Aurora Spine Corporation, Globus Medical, Inc., Medtronic plc., and Tenon Medical, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 6 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
GMED is currently a Follower in the organic co-movement group Medical Devices. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
No durable theme membership has been observed for this name yet.